My first question is whether the FY '30 guidance in terms of revenue and profitability is still standing in view of the muted Q1 and Q2 results?
So the guidance stands?
Questions across 4 calls
Vinod Jain
WF Advisors
Piramal Pharma Limited
The incidence of taxation has been high for the years '23 -'24 and '24-'25. Now my question is largely answered that the incidence would go down over the years to more normalized 24%, 25% tax incidence up to in the financial year 2030. But what is the specific guidance you can give for the year '25 -'26? Will the tax incidence be lower significantly from the earlier 2 years?
Very well. That answers my question.
Yes. My question is only related to the taxation. Why is the tax incident so high in the quarter?
Okay.
This is gratifying to know that the company is turning around in terms of profitability. The issue I want to address is the Q1, Q2, Q3, Q4 phenomena of the company wherein the Q1 is having the lowest performance and Q4 has the best performance. Now this, I believe the skewed performance affects the overall profitability of the company. I have a point that there is no slide to explain this phenomena and what is the view to be taken on this going forward?
So, can we expect that Q1, Q2 may be negative in terms of profitability and then Q3, Q4 would be positive?